The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
Open accessAbstract
BACKGROUND: Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the reversal of the effects of these drugs. Andexanet is designed to reverse the anticoagulant effects of factor Xa inhibitors. METHODS: Healthy older volunteers were given 5 mg of apixaban twice daily or 20 mg of rivaroxaban daily. For each factor Xa inhibitor, a two-part randomized placebo-controlled study was conducted to evaluate andexanet administered as a bolus or as a bolus plus a 2-hour infusion. The primary outcome was the mean percent change in anti-factor Xa activity, which is a measure of factor Xa inhibition by the anticoagulant. RESULTS: Among the apixaban-treated participants, anti-factor Xa activity was reduced by 94% among those who received an andexanet bolus (24 participants), as compared with 21% among those who received placebo (9 participants) (P<0.001), and unbound apixaban concentration was reduced by 9.3 ng per milliliter versus 1.9 ng per milliliter (P<0.001); thrombin generation was fully restored in 100% versus 11% of the participants (P<0.001) within 2 to 5 minutes. Among the rivaroxaban-treated participants, anti-factor Xa activity was reduced by 92% among those who received an andexanet bolus (27 participants), as compared with 18% among those who received placebo (14 participants) (P<0.001), and unbound rivaroxaban concentration was reduced by 23.4 ng per milliliter versus 4.2 ng per milliliter (P<0.001); thrombin generation was fully restored in 96% versus 7% of the participants (P<0.001). These effects were sustained when andexanet was administered as a bolus plus an infusion. In a subgroup of participants, transient increases in levels of d-dimer and prothrombin fragments 1 and 2 were observed, which resolved within 24 to 72 hours. No serious adverse or thrombotic events were reported. CONCLUSIONS: Andexanet reversed the anticoagulant activity of apixaban and rivaroxaban in older healthy participants within minutes after administration and for the duration of infusion, without evidence of clinical toxic effects. (Funded by Portola Pharmaceuticals and others; ANNEXA-A and ANNEXA-R ClinicalTrials.gov numbers, NCT02207725 and NCT02220725.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Andexanet alpha, a modified recombinant human factor Xa that lacks enzymatic activity, reverses the anticoagulant activity of apixaban and rivaroxaban in healthy probands within minutes after administration and for the duration of infusion, with a transient increase in markers of coagulation activity of uncertain clinical relevance.508”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [508]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Idarucizumab for Dabigatran Reversal
Pollack, C. V., Reilly, P. A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kamphuisen, P. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502000 · Cited by 1,552
Idarucizumab for dabigatran reversal
Garrett, A. D., PharmD, & Bcps (2015) · Cited by 1,169
Lu, G., DeGuzman, F. R., Hollenbach, S. J., Karbarz, M. J., Abe, K. Y., Lee, G., Luan, P., Hutchaleelaha, A., Inagaki, M., Conley, P. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3102 · Cited by 700
Self-citationProbability Tables for Individual Comparisons by Ranking Methods
Wilcoxon, F. (1947) · Biometrics · doi:10.2307/3001946 · Cited by 578
MicroRNA-328 Contributes to Adverse Electrical Remodeling in Atrial Fibrillation
Lu, Y., Zhang, Y., Wang, N., Pan, Z., Gao, X., Zhang, F., Zhang, Y., Shan, H., Luo, X., Bai, Y., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.958967 · Cited by 450
Beyer‐Westendorf, J., Förster, K., Pannach, S., Ebertz, F., Gelbricht, V., Thieme, C., Michalski, F., Köhler, C. U., Werth, S., Şahin, K., et al. (2014) · Blood · doi:10.1182/blood-2014-03-563577 · Cited by 408
Pernod, G., Albaladejo, P., Godiér, A., Samama, C. M., Susen, S., Gruel, Y., Blais, N., Fontana, P., Cohen, A. A., Llau, J. V., et al. (2013) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.04.009 · Cited by 310
Research works printed but not linked: 1
- Crowther MA, 2013, J Thromb Haemost, 11, OC 20.1
Cited by
Sorted by citations
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P. F., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castellà, M., Diener, H., Heidbüchel, H., Hendriks, J., et al. (2016) · EP Europace · doi:10.1093/europace/euw295 · Cited by 6,438
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000923 · Cited by 3,686
Calkins, H. G., Hindricks, G., Cappato, R., Kim, Y., Saad, E., Aguinaga, L., Akar, J. G., Badhwar, V., Brugada, J., Camm, A. J., et al. (2017) · Heart Rhythm · doi:10.1016/j.hrthm.2017.05.012 · Cited by 2,794
January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000665 · Cited by 2,744
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000932 · Cited by 2,449
January, C. T., Wann, L. S., Calkins, H. G., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.011 · Cited by 2,252
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H. M., Krieger, E. V., Mack, M. J., McLeod, C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.018 · Cited by 2,110
Rossaint, R., Bouillon, B., Černý, V., Coats, T., Duranteau, J., Fernández‐Mondejar, E., Filipescu, D. C., Hunt, B. J., Komadina, R., Nardi, G., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1265-x · Cited by 1,495
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw313 · Cited by 1,403
Spahn, D. R., Bouillon, B., Černý, V., Duranteau, J., Filipescu, D. C., Hunt, B. J., Komadina, R., Maegele, M., Nardi, G., Riddez, L., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2347-3 · Cited by 1,323
Hankey, G. J. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30962-x · Cited by 1,311
Calkins, H. G., Hindricks, G., Cappato, R., Kim, Y., Saad, E., Aguinaga, L., Akar, J. G., Badhwar, V., Brugada, J., Camm, A. J., et al. (2017) · EP Europace · doi:10.1093/europace/eux274 · Cited by 1,203
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H. M., Krieger, E. V., Mack, M. J., McLeod, C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.035 · Cited by 1,119
Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update
An, S. J., Kim, T. J., & Yoon, B. W. (2017) · Journal of Stroke · doi:10.5853/jos.2016.00864 · Cited by 1,049
Deep vein thrombosis and pulmonary embolism
Nisio, M. D., van Es, N., & Buller, H. R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30514-1 · Cited by 1,046
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
Connolly, S. J., Crowther, M. A., Eikelboom, J. W., Gibson, C. M., Curnutte, J. T., Lawrence, J. H., Yue, P., Bronson, M. D., Lu, G., Conley, P. B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814051 · Cited by 977
Self-citationAndexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
Connolly, S. J., Milling, T. J., Eikelboom, J. W., Gibson, C. M., Curnutte, J. T., Gold, A., Bronson, M. D., Lu, G., Conley, P. B., Verhamme, P. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607887 · Cited by 812
Self-citationManagement of severe perioperative bleeding
Kozek‐Langenecker, S. A., Ahmed, A. B., Afshari, A., Albaladejo, P., Aldecoa, C., Barauskas, G., ROBERTIS, E. D., Faraoni, D., Filipescu, D. C., Fries, D. R., et al. (2017) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000000630 · Cited by 817
Tzeis, S. E., Gerstenfeld, E. P., Kalman, J. M., Saad, E., Shamloo, A. S., Andrade, J. G., Barbhaiya, C. R., Baykaner, T., Bovéda, S., Calkins, H. G., et al. (2024) · EP Europace · doi:10.1093/europace/euae043 · Cited by 724
Andrade, J. G., Aguilar, M., Atzema, C. L., Bell, A., Cairns, J. A., Cheung, C. C., Cox, J. L., Dorian, P., Gladstone, D. J., Healey, J. S., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.09.001 · Cited by 593
Chao, T., Joung, B., Takahashi, Y., Lim, T. W., Choi, E., Chan, Y., Guo, Y., Sriratanasathavorn, C., Oh, S., Okumura, K., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0041-1739411 · Cited by 476
Doherty, J. U., Gluckman, T. J., Hucker, W. J., Januzzi, J. L., Ortel, T. L., Saxonhouse, S. J., & Spinler, S. A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.024 · Cited by 449
Kamel, H., & Healey, J. S. (2017) · Circulation Research · doi:10.1161/circresaha.116.308407 · Cited by 456
January, C. T., Wann, L. S., Calkins, H. G., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Heart Rhythm · doi:10.1016/j.hrthm.2019.01.024 · Cited by 414
Mazzolai, L., Aboyans, V., Ageno, W., Agnelli, G., Alatri, A., Bauersachs, R., Brekelmans, M. P. A., Büller, H. R., Elias, A., Farge, D., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx003 · Cited by 402
2017 EACTS Guidelines on perioperative medication in adult cardiac surgery
Sousa‐Uva, M., Head, S. J., Milojevic, M., Collet, J., Landoni, G., Castellà, M., Dunning, J., Guðbjartsson, T., Linker, N., Sandoval, E., et al. (2017) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx314 · Cited by 415
Levy, J. H., Ageno, W., Chan, N., Crowther, M. A., Verhamme, P. B., & Weitz, J. I. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13227 · Cited by 377
Self-citationInterventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications
Narouze, S., Benzon, H. T., Provenzano, D. A., Buvanendran, A., Andrés, J. A. D., Deer, T. R., Rauck, R. L., & Huntoon, M. A. (2015) · Regional Anesthesia & Pain Medicine · doi:10.1097/aap.0000000000000223 · Cited by 366
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
Byon, W., Merali, S. J., Boyd, R. A., & Frost, C. E. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00775-z · Cited by 373
Tomaselli, G. F., Mahaffey, K. W., Cuker, A. C., Dobesh, P. P., Doherty, J. U., Eikelboom, J. W., Florido, R., Hucker, W. J., Mehran, R., Messe, S. R., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.1085 · Cited by 348
Self-citationMajeed, A., Ågren, A., Holmström, M., Bruzelius, M., Chaireti, R., Odeberg, J., Hempel, E.-L., Magnusson, M., Frisk, T., & Schulman, S. (2017) · Blood · doi:10.1182/blood-2017-05-782060 · Cited by 330
Tzeis, S. E., Gerstenfeld, E. P., Kalman, J. M., Saad, E., Shamloo, A. S., Andrade, J. G., Barbhaiya, C. R., Baykaner, T., Bovéda, S., Calkins, H. G., et al. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.03.017 · Cited by 323
Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage
Connolly, S. J., Sharma, M., Cohen, A. T., Demchuk, A. M., Członkowska, A., Lindgren, A. G., Molina, C. A., Bereczki, D., Toni, D., Seiffge, D. J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313040 · Cited by 284
Self-citation2020 ACC/AHA guideline for the management of patients with valvular heart disease
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2021.04.002 · Cited by 279
Macle, L., Cairns, J. A., Leblanc, K., Tsang, T. S. M., Skanes, A. C., Cox, J. L., Healey, J. S., Bell, A., Pilote, L., Andrade, J. G., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.591 · Cited by 275
Self-citationRaval, A. N., Cigarroa, J. E., Chung, M. K., Díaz‐Sandoval, L. J., Diercks, D., Piccini, J. P., Jung, H. S., Washam, J. B., Welch, B. G., Zazulia, A. R., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000477 · Cited by 251
Intagliata, N. M., Henry, Z. H., Maitland, H. S., Shah, N. L., Argo, C. K., Northup, P. G., & Caldwell, S. H. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-4012-2 · Cited by 250
Management of Intracerebral Hemorrhage
Schrag, M., & Kirshner, H. S. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.066 · Cited by 253
Andrade, J. G., Verma, A., Mitchell, L. B., Parkash, R., Leblanc, K., Atzema, C. L., Healey, J. S., Bell, A., Cairns, J. A., Connolly, S. J., et al. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.08.026 · Cited by 242
Self-citationApixaban Pharmacokinetics at Steady State in Hemodialysis Patients
Mavrakanas, T. A., Samer, C. F., Nessim, S. J., Frisch, G., & Lipman, M. L. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016090980 · Cited by 231
Peri‐operative management of anticoagulation and antiplatelet therapy
Keeling, D. M., Tait, R. C., & Watson, H. G. (2016) · British Journal of Haematology · doi:10.1111/bjh.14344 · Cited by 227
Douxfils, J., Adcock, D. M., Bates, S. M., Favaloro, E. J., Gouin‐Thibault, I., Guillermo, C., Kawai, Y., Lindhoff‐Last, E., Kitchen, S., & Gosselin, R. C. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1450-8178 · Cited by 212
2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation
Chiang, C., Okumura, K., Zhang, S., Chao, T., Siu, C., Lim, T. W., Saxena, A., Takahashi, Y., & Teo, W. S. (2017) · Journal of Arrhythmia · doi:10.1016/j.joa.2017.05.004 · Cited by 200
Peden, C. J., Aggarwal, G., Aitken, R., Anderson, I. D., Foss, N. B., Cooper, Z. R., Dhesi, J. K., French, W. B., Grant, M. C., Hammarqvist, F., et al. (2021) · World Journal of Surgery · doi:10.1007/s00268-021-05994-9 · Cited by 200
Intagliata, N. M., Argo, C. K., Stine, J. G., Lisman, T., Caldwell, S. H., Violi, F., & Disease, O. B. O. T. F. O. T. 7. I. C. I. L. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1666861 · Cited by 180
Li, Q., Yakhkind, A., Alexandrov, A. W., Alexandrov, A. V., Anderson, C. S., Dowlatshahi, D. D., Frontera, J. A., Hemphill, J. C., Ganti, L., Kellner, C. P., et al. (2023) · Stroke · doi:10.1161/strokeaha.123.043033 · Cited by 178
Current management of spontaneous intracerebral haemorrhage
Dastur, C. K., & Yu, W. (2017) · Stroke and Vascular Neurology · doi:10.1136/svn-2016-000047 · Cited by 179
Montaño, A., Hanley, D. F., & Hemphill, J. C. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64034-5.00019-5 · Cited by 194
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors
Milling, T. J., Middeldorp, S., Xu, L., Koch, B., Demchuk, A. M., Eikelboom, J. W., Verhamme, P. B., Cohen, A. T., Beyer‐Westendorf, J., Gibson, C. M., et al. (2023) · Circulation · doi:10.1161/circulationaha.121.057844 · Cited by 174
Self-citationNarouze, S., Benzon, H. T., Provenzano, D. A., Buvanendran, A., Andrés, J. A. D., Deer, T. R., Rauck, R. L., & Huntoon, M. A. (2017) · Regional Anesthesia & Pain Medicine · doi:10.1097/aap.0000000000000700 · Cited by 175
Eikelboom, J. W., Quinlan, D. J., van Ryn, J., & Weitz, J. I. (2015) · Circulation · doi:10.1161/circulationaha.115.019628 · Cited by 162
Outcome of intracerebral hemorrhage associated with different oral anticoagulants
Wilson, D., Seiffge, D. J., Traenka, C., Basir, G. S., Purrucker, J. C., Rizos, T., Sobowale, O. A., Sallinen, H., Yeh, S., Wu, T. Y., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003886 · Cited by 155
Christensen, H., Cordonnier, C., Kõrv, J., Lal, A., Ovesen, C., Purrucker, J. C., Toni, D., & Steiner, T. (2019) · European Stroke Journal · doi:10.1177/2396987319849763 · Cited by 162
Zirlik, A., & Bode, C. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1446-0 · Cited by 158
Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban
Ansell, J., Bakhru, S., Laulicht, B., Steiner, S. S., GROSSO, M. A., Brown, K. D., Dishy, V., Lanz, H., Mercuri, M. F., Noveck, R. J., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-03-0224 · Cited by 146
Reversal agents for non-vitamin K antagonist oral anticoagulants
Levy, J. H., Douketis, J. D., & Weitz, J. I. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.223 · Cited by 141
Chiang, C., Wu, T.-J., Ueng, K.-C., Chao, T., Chang, K., Wang, C.-C., Lin, Y., Yin, W., Kuo, J., Lin, W., et al. (2016) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2016.10.005 · Cited by 138
Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers
Bhatt, D. L., Pollack, C. V., Weitz, J. I., Jennings, L. K., Xu, S., Arnold, S. E., Umstead, B. R., Mays, M. C., & Lee, J. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901778 · Cited by 139
JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias
Ono, K., Iwasaki, Y., Akao, M., Ikeda, T., Ishii, K., Inden, Y., Kusano, K., Kobayashi, Y., Koretsune, Y., Sasano, T., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-20-1212 · Cited by 132
Advances in Therapeutic Approaches for Spontaneous Intracerebral Hemorrhage
Al‐Kawaz, M., Hanley, D. F., & Ziai, W. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00902-w · Cited by 130
Spontaneous Intracerebral Hemorrhage: Management
Kim, J. Y., & Bae, H. (2017) · Journal of Stroke · doi:10.5853/jos.2016.01935 · Cited by 131
Hematoma Expansion in Intracerebral Hemorrhage: An Update on Prediction and Treatment
Li, Z., You, M., Long, C., Bi, R., Xu, H., He, Q., & Hu, B. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00702 · Cited by 128
Piran, S., Khatib, R., Schulman, S., Majeed, A., Holbrook, A. M., Witt, D. M., Wiercioch, W., Schünemann, H. J., & Nieuwlaat, R. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018024133 · Cited by 126
Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants
Eikelboom, J. W., Kozek‐Langenecker, S. A., Exadaktylos, A., Bátorová, A., Boda, Z., Christory, F., Gornik, I., Kėkštas, G., Kher, A., Komadina, R., et al. (2017) · British Journal of Anaesthesia · doi:10.1016/j.bja.2017.11.082 · Cited by 125
Adeboyeje, G., Sylwestrzak, G., Barron, J. J., White, J., Rosenberg, A., Abarca, J., Crawford, G., & Redberg, R. F. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.9.968 · Cited by 126
Andexanet Alfa: First Global Approval
Heo, Y. (2018) · Drugs · doi:10.1007/s40265-018-0940-4 · Cited by 119
Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants
Kanuri, S. H., & Kreutz, R. P. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9010007 · Cited by 119
Ntaios, G., Papavasileiou, V., Diener, H.-C., Makaritsis, K. P., & Michel, P. (2017) · International Journal of Stroke · doi:10.1177/1747493017700663 · Cited by 117
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy
Lópes, R. D., Guimarães, P. O., Kolls, B. J., WOJDYLA, D. M., Bushnell, C., Hanna, M., Easton, J. D., Thomas, L. E., Wallentin, L. C., Al‐Khatib, S. M., et al. (2017) · Blood · doi:10.1182/blood-2016-08-731638 · Cited by 114
Perioperative management of patients on direct oral anticoagulants
Dubois, V., Dincq, A.-S., Douxfils, J., Ickx, B., Samama, C. M., Dogné, J., Gourdin, M. J., Châtelain, B., Mullier, F., & Lessire, S. (2017) · Thrombosis Journal · doi:10.1186/s12959-017-0137-1 · Cited by 114
Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting
Ghadimi, K., Levy, J. H., & Welsby, I. J. (2016) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000001188 · Cited by 111
Evolving Treatments for Arterial and Venous Thrombosis
Chan, N., Eikelboom, J. W., & Weitz, J. I. (2016) · Circulation Research · doi:10.1161/circresaha.116.306925 · Cited by 113
Ruff, C. T., Giugliano, R. P., & Antman, E. M. (2016) · Circulation · doi:10.1161/circulationaha.116.021831 · Cited by 109
Synthetic oligosaccharides can replace animal-sourced low–molecular weight heparins
Xu, Y., Chandarajoti, K., Zhang, X., Pagadala, V., Dou, W., Hoppensteadt, D., Sparkenbaugh, E., Cooley, B. C., Daily, S., Key, N. S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5954 · Cited by 106
New developments in anticoagulants: Past, present and future
Weitz, J. I., & Harenberg, J. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-10-0807 · Cited by 105
Chao, T., Joung, B., Takahashi, Y., Lim, T. W., Choi, E., Chan, Y., Guo, Y., Sriratanasathavorn, C., Oh, S., Okumura, K., et al. (2021) · Journal of Arrhythmia · doi:10.1002/joa3.12652 · Cited by 105
The Role of TEG and ROTEM in Damage Control Resuscitation
Brill, J. B., Brenner, M., Duchesne, J., Roberts, D., Ferrada, P., Horer, T., Kauvar, D. S., Khan, M. A., Kirkpatrick, A., Ordoñez, C. A., et al. (2021) · Shock · doi:10.1097/shk.0000000000001686 · Cited by 96
Deer, T. R., Narouze, S., Provenzano, D. A., Pope, J. E., Falowski, S. M., Russo, M. A., Benzon, H. T., Slavin, K. V., Pilitsis, J. G., Alò, K. M., et al. (2017) · Neuromodulation Technology at the Neural Interface · doi:10.1111/ner.12542 · Cited by 92
Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease
Jain, N., & Reilly, R. F. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02170218 · Cited by 94
Angiolillo, D. J., Goodman, S. G., Bhatt, D. L., Eikelboom, J. W., Price, M. J., Moliterno, D. J., Cannon, C. P., Tanguay, J., Granger, C. B., Mauri, L., et al. (2016) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.116.004395 · Cited by 90
DOACs – advances and limitations in real world
Lee, L. H. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0111-3 · Cited by 91
Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience
Eikelboom, J. W., & Merli, G. J. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.06.003 · Cited by 90
Rose, D., & Bar, B. (2018) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2018.04.004 · Cited by 90
Tummala, R., Kavtaradze, A., Gupta, A., & Ghosh, R. K. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.03.056 · Cited by 86
A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery
Milling, T. J., & Ziebell, C. M. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.03.004 · Cited by 82
Emergency Reversal of Anticoagulation
Yee, J., & Kaide, C. G. (2019) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2018.5.38235 · Cited by 81
Ammar, A. A., Ammar, M. A., Owusu, K. A., Brown, S. C., Kaddouh, F., Elsamadicy, A. A., Acosta, J., & Falcone, G. J. (2021) · Neurocritical Care · doi:10.1007/s12028-020-01161-5 · Cited by 79
Bliden, K. P., Chaudhary, R., Mohammed, N., Muresan, A. A., Lopez-Espina, C. G., Cohen, E., Raviv, G., Doubleday, M., Zaman, F., Mathew, B., et al. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1477-1 · Cited by 78
Direct oral anticoagulants versus warfarin: is new always better than the old?
Burn, J., & Pirmohamed, M. (2018) · Open Heart · doi:10.1136/openhrt-2017-000712 · Cited by 79
Tzeis, S. E., Gerstenfeld, E. P., Kalman, J. M., Saad, E., Shamloo, A. S., Andrade, J. G., Barbhaiya, C. R., Baykaner, T., Bovéda, S., Calkins, H. G., et al. (2024) · Journal of Arrhythmia · doi:10.1002/joa3.13082 · Cited by 76
Treatment of Venous Thromboembolism With New Anticoagulant Agents
Becattini, C., & Agnelli, G. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.072 · Cited by 78
Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage
Kuramatsu, J. B., Sembill, J. A., & Huttner, H. B. (2019) · Critical Care · doi:10.1186/s13054-019-2492-8 · Cited by 77
Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa
Siegal, D. M., Lu, G., Leeds, J. M., Karbarz, M. J., Castillo, J., Mathur, V. S., Hutchaleelaha, A., Sinha, U., Kitt, M. M., McClure, M. W., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007112 · Cited by 74
Self-citationReversal of direct oral anticoagulants: guidance from the SSC of the ISTH
Levy, J. H., Shaw, J. R., Castellucci, L. A., Connors, J. M., Douketis, J. D., Lindhoff‐Last, E., Rocca, B., Samama, C. M., Siegal, D. M., & Weitz, J. I. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.07.009 · Cited by 73
Self-citationAdherence to long‐term anticoagulation treatment, what is known and what the future might hold
Bartoli-Abdou, J., Auyeung, V., Patel, J. P., & Arya, R. (2016) · British Journal of Haematology · doi:10.1111/bjh.14134 · Cited by 73
Direct oral anticoagulants: a review on the current role and scope of reversal agents
Chaudhary, R., Sharma, T., Garg, J., Sukhi, A., Bliden, K. P., Tantry, U. S., Turagam, M. K., Lakkireddy, D., & Gurbel, P. A. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01954-2 · Cited by 72
Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants
Touzé, E., Gruel, Y., Gouin‐Thibault, I., de Maistre, E., Susen, S., Siè, P., & Derex, L. (2018) · European Journal of Neurology · doi:10.1111/ene.13582 · Cited by 71
Zeeshan, M., Jehan, F., O’Keeffe, T., Khan, M., Zakaria, E. R., Hamidi, M., Gries, L. M., Kulvatunyou, N., & Joseph, B. A. (2018) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000001995 · Cited by 71
Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass
Gunaratne, R., Kumar, S., Frederiksen, J. W., Stayrook, S. E., Lohrmann, J., Perry, K., Bompiani, K. M., Chabata, C. V., Thalji, N. K., Ho, M., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4153 · Cited by 71
Metadata
- Authors
- Siegal, D. M., Curnutte, J. T., Connolly, S. J., Lu, G., Conley, P. B., Wiens, B. L., Mathur, V. S., Castillo, J., Bronson, M. D., Leeds, J. M., Mar, F. A., Gold, A., & Crowther, M. A.
- Affiliations
- Population Health Research Institute (CA)
- Portola Pharmaceuticals (United States) (US)
- McMaster University (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-12-17
- Volume
- 373
- Issue
- 25
- Pages
- 2413-2424
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2174386486
- Cited by
- 1,047
- References
- 22
- Citations by year
- 2026: 21 · 2025: 34 · 2024: 48 · 2023: 56 · 2022: 44 · 2021: 57 · 2020: 91 · 2019: 126 · 2018: 133 · 2017: 175 · 2016: 249 · 2015: 11
- FWCI
- 137.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- andexanet alfa, factor Xa inhibitors, apixaban, rivaroxaban, anticoagulant reversal, bleeding complications, anti-Xa activity, thrombin generation, unbound drug concentration, D-dimer, prothrombin fragments, older adults, drug safety, pharmacokinetics, pharmacodynamics, thromboprophylaxis, thrombolysis
- MeSH terms
- Rivaroxaban, Administration, Oral, Aged, Antidotes, Blood Coagulation, Double-Blind Method, Female, Hemorrhage, Humans, Male, Middle Aged, Peptide Fragments, Protein Precursors, Prothrombin, Pyrazoles, Pyridones, Recombinant Proteins, Factor Xa, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
